Findings

What do systematic reviews say?

1,923 questions · 1,956 findings · 143 reviews · Musculoskeletal

Sort:Best matchNewestHighest certainty Download CSV

No studies found 555 · 28.4%GRADE not reported 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%

Intervention not reported

Radiographic joint changes · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events Participants (n) reported serious adverse events · patients with treating osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · patients with osteoarthritis

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 357 participants
Low

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Function (short‐term) WOMAC scale from: 0 to 100 (higher is worse function). · patients with osteoarthritis

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 357 participants
Low

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Adverse events Participants (n) reported adverse events · patients with osteoarthritis

Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported adverse events compared with chondroitin sulphate (low certainty).

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
RR 0.86 [0.59, 1.26]
1 study · 357 participants
Low

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Withdrawals due to adverse events · patients with osteoarthritis

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 357 participants
GRADE not reported

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis

Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported serious adverse events compared with chondroitin sulphate (low certainty).

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
RR 2.92 [0.31, 27.78]
1 study · 357 participants
Low

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Radiographic joint changes · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Quality of life · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Radiographic joint changes · patients with treating osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · patients with treating osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Pain Global pain VAS 0‐100 (higher scores mean worse) · patients with treating osteoarthritis

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 85 participants
Moderate

Intervention not reported

Function WOMAC‐VAS (Function) · patients with treating osteoarthritis

1 finding from 1 review

Oral herbal therapies for treating osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 85 participants
Moderate

Oral or transdermal opioids vs placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Patients with osteoarthritis of the knee or hip

Oral or transdermal opioids showed no clear difference in pain intensity Various pain scales. (median compared with placebo (high certainty).

1 finding from 1 review

Oral or transdermal opioids for osteoarthritis of the knee or hip 2014 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 8275 participants
High

Oral or transdermal opioids vs placebo

Function Various validated function scales. · Patients with osteoarthritis of the knee or hip

Oral or transdermal opioids showed no clear difference in function Various validated function scales. (median compared with placebo (high certainty).

1 finding from 1 review

Oral or transdermal opioids for osteoarthritis of the knee or hip 2014 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 3553 participants
High

Oral or transdermal opioids vs placebo

Adverse events as N of participants with at least one adverse event objective · Patients with osteoarthritis of the knee or hip

Oral or transdermal opioids probably leads to higher number of participants experiencing any adverse event (median compared with placebo (moderate certainty).

1 finding from 1 review

Oral or transdermal opioids for osteoarthritis of the knee or hip 2014 · Cochrane Headline outcomes only
RR 1.49 [1.35, 1.63]
9 studies · 4898 participants
Moderate

Oral or transdermal opioids vs placebo

Number of patients who withdrew because of adverse events · Patients with osteoarthritis of the knee or hip

Oral or transdermal opioids leads to higher number of participants who withdrew because of adverse events (median compared with placebo (high certainty).

1 finding from 1 review

Oral or transdermal opioids for osteoarthritis of the knee or hip 2014 · Cochrane Headline outcomes only
RR 3.76 [2.93, 4.82]
19 studies · 7712 participants
High

Oral or transdermal opioids vs placebo

Number of participants experiencing any serious adverse events · Patients with osteoarthritis of the knee or hip

Oral or transdermal opioids showed no clear difference in number of participants experiencing any serious adverse event (median compared with placebo (low certainty).

1 finding from 1 review

Oral or transdermal opioids for osteoarthritis of the knee or hip 2014 · Cochrane Headline outcomes only
RR 3.35 [0.83, 13.56]
3 studies · 681 participants
Low

Oral or transdermal opioids vs placebo

Withdrawal symptoms · Patients with osteoarthritis of the knee or hip

Oral or transdermal opioids probably leads to higher withdrawal symptoms (median compared with placebo (moderate certainty).

1 finding from 1 review

Oral or transdermal opioids for osteoarthritis of the knee or hip 2014 · Cochrane Headline outcomes only
OR 2.67 [2.02, 3.77]
3 studies · 1151 participants
Moderate